TY  - JOUR
AU  - Leon-Lopez, Rafael
AU  - Carcel-Fernandez, Sheila 
AU  - Limia-Perez, Laura
AU  - Romero-Palacios, Alberto
AU  - Fernandez-Roldan, Maria Concepcion
AU  - Aguilar-Alonso, Eduardo
AU  - Perez-Camacho, Ines
AU  - Rodriguez-Baño, Jesus
AU  - Merchante, Nicolas
AU  - Olalla, Julian
AU  - Esteban-Moreno, M Angeles
AU  - Santos, Marta
AU  - Luque-Pineda, Antonio
AU  - Torre-Cisneros, Julian
PY  - 2020
DO  - 10.1136/bmjopen-2020-039951
UR  - http://hdl.handle.net/10668/16603
T2  - BMJ open
AB  - About 25% of patients with COVID-19 develop acute respiratory distress syndrome (ARDS) associated with a high release of pro-inflammatory cytokines such as interleukin-6 (IL-6). The aim of the SARICOR study is to demonstrate that early administration...
LA  - en
PB  - BMJ Group
KW  - Adult intensive & critical care
KW  - Infectious diseases
KW  - Internal medicine
KW  - Virology
KW  - Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
KW  - Area de Gestión Sanitaria Sur de Córdoba
KW  - Área de Gestión Sanitaria Sur de Sevilla
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antibodies, monoclonal, humanized
KW  - Betacoronavirus
KW  - COVID-19
KW  - Clinical trials, phase II as topic
KW  - Coronavirus infections
KW  - Cytokine release syndrome
KW  - Female
KW  - Fibrin fibrinogen degradation products
KW  - Humans
KW  - Interleukin-6
KW  - Male
KW  - Middle aged
KW  - Multicenter studies as topic
KW  - Pandemics
KW  - Pneumonia, viral
KW  - Randomized controlled trials as topic
KW  - Respiration, artificial
KW  - Respiratory distress syndrome
KW  - SARS-CoV-2
KW  - Young adult
KW  - COVID-19 drug treatment
TI  - Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
TY  - research article
VL  - 10
ER  -